Literature DB >> 29706455

Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells.

Jeonghyun Ahn1, Tianli Xia1, Ailem Rabasa Capote1, Dillon Betancourt1, Glen N Barber2.   

Abstract

The ability of dying cells to activate antigen-presenting cells (APCs) is carefully controlled to avoid unwarranted inflammatory responses. Here, we show that engulfed cells containing cytosolic double-stranded DNA species (viral or synthetic) or cyclic di-nucleotides (CDNs) are able to stimulate APCs via extrinsic STING (stimulator of interferon genes) signaling, to promote antigen cross-presentation. In the absence of STING agonists, dying cells were ineffectual in the stimulation of APCs in trans. Cytosolic STING activators, including CDNs, constitute cellular danger-associated molecular patterns (DAMPs) only generated by viral infection or following DNA damage events that rendered tumor cells highly immunogenic. Our data shed insight into the molecular mechanisms that drive appropriate anti-tumor adaptive immune responses, while averting harmful autoinflammatory disease, and provide a therapeutic strategy for cancer treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  STING; STING-dependent adjuvants (STAVs); anti-tumor T cells; antigen-presenting cells (APCs); cyclic di-nucleotides (CDNs); innate immunity; interferon

Mesh:

Substances:

Year:  2018        PMID: 29706455      PMCID: PMC6177226          DOI: 10.1016/j.ccell.2018.03.027

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  35 in total

Review 1.  How dying cells alert the immune system to danger.

Authors:  Hajime Kono; Kenneth L Rock
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

2.  Intrinsic self-DNA triggers inflammatory disease dependent on STING.

Authors:  Jeonghyun Ahn; Phillip Ruiz; Glen N Barber
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

Review 3.  Dying cells actively regulate adaptive immune responses.

Authors:  Nader Yatim; Sean Cullen; Matthew L Albert
Journal:  Nat Rev Immunol       Date:  2017-03-13       Impact factor: 53.106

4.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

Review 5.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

Review 6.  STING-dependent cytosolic DNA sensing pathways.

Authors:  Glen N Barber
Journal:  Trends Immunol       Date:  2013-12-02       Impact factor: 16.687

7.  STING manifests self DNA-dependent inflammatory disease.

Authors:  Jeonghyun Ahn; Delia Gutman; Shinobu Saijo; Glen N Barber
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-06       Impact factor: 11.205

8.  cGAS surveillance of micronuclei links genome instability to innate immunity.

Authors:  Karen J Mackenzie; Paula Carroll; Carol-Anne Martin; Olga Murina; Adeline Fluteau; Daniel J Simpson; Nelly Olova; Hannah Sutcliffe; Jacqueline K Rainger; Andrea Leitch; Ruby T Osborn; Ann P Wheeler; Marcin Nowotny; Nick Gilbert; Tamir Chandra; Martin A M Reijns; Andrew P Jackson
Journal:  Nature       Date:  2017-07-24       Impact factor: 49.962

Review 9.  Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.

Authors:  Mathieu P Rodero; Yanick J Crow
Journal:  J Exp Med       Date:  2016-11-07       Impact factor: 14.307

10.  Cytoplasmic chromatin triggers inflammation in senescence and cancer.

Authors:  Zhixun Dou; Kanad Ghosh; Maria Grazia Vizioli; Jiajun Zhu; Payel Sen; Kirk J Wangensteen; Johayra Simithy; Yemin Lan; Yanping Lin; Zhuo Zhou; Brian C Capell; Caiyue Xu; Mingang Xu; Julia E Kieckhaefer; Tianying Jiang; Michal Shoshkes-Carmel; K M Ahasan Al Tanim; Glen N Barber; John T Seykora; Sarah E Millar; Klaus H Kaestner; Benjamin A Garcia; Peter D Adams; Shelley L Berger
Journal:  Nature       Date:  2017-10-04       Impact factor: 49.962

View more
  52 in total

1.  Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.

Authors:  Nina Marí Gual Pimenta de Queiroz; Tianli Xia; Hiroyasu Konno; Glen N Barber
Journal:  Mol Cancer Res       Date:  2018-12-26       Impact factor: 5.852

Review 2.  Harnessing innate immunity in cancer therapy.

Authors:  Olivier Demaria; Stéphanie Cornen; Marc Daëron; Yannis Morel; Ruslan Medzhitov; Eric Vivier
Journal:  Nature       Date:  2019-10-02       Impact factor: 49.962

Review 3.  STING pathway agonism as a cancer therapeutic.

Authors:  Blake A Flood; Emily F Higgs; Shuyin Li; Jason J Luke; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

4.  Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.

Authors:  Daniel Shae; Jessalyn J Baljon; Mohamed Wehbe; Plamen P Christov; Kyle W Becker; Amrendra Kumar; Naveenchandra Suryadevara; Carcia S Carson; Christian R Palmer; Frances C Knight; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2020-07-31       Impact factor: 15.881

5.  cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.

Authors:  Zining Wang; Jiemin Chen; Jie Hu; Hongxia Zhang; Feifei Xu; Wenzhuo He; Xiaojuan Wang; Mengyun Li; Wenhua Lu; Gucheng Zeng; Penghui Zhou; Peng Huang; Siyu Chen; Wende Li; Liang-Ping Xia; Xiaojun Xia
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

6.  LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance.

Authors:  Larissa D Cunha; Mao Yang; Robert Carter; Clifford Guy; Lacie Harris; Jeremy C Crawford; Giovanni Quarato; Emilio Boada-Romero; Halime Kalkavan; Michael D L Johnson; Sivaraman Natarajan; Meghan E Turnis; David Finkelstein; Joseph T Opferman; Charles Gawad; Douglas R Green
Journal:  Cell       Date:  2018-09-20       Impact factor: 41.582

Review 7.  Macrophages as regulators of tumour immunity and immunotherapy.

Authors:  David G DeNardo; Brian Ruffell
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

8.  Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.

Authors:  Junzhong Lai; Yajuan Fu; Shuoran Tian; Shanlu Huang; Xuan Luo; Lili Lin; Xing Zhang; Hanze Wang; Zhang Lin; Heng Zhao; Shujin Lin; Junhong Zhao; Shan Xu; Daliang Li; Shaoli Cai; Luna Dong; Jing Qian; Jiadi Liang; Qiumei Li; Yong Zhang; Jiqiang Fan; Robert Balderas; Qi Chen
Journal:  Mol Ther       Date:  2021-02-09       Impact factor: 11.454

9.  Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles.

Authors:  Kyle M Garland; Sema Sevimli; Kameron V Kilchrist; Craig L Duvall; Rebecca S Cook; John T Wilson
Journal:  Cell Mol Bioeng       Date:  2019-05-03       Impact factor: 2.321

Review 10.  STING and transplantation: can targeting this pathway improve outcomes?

Authors:  Cameron S Bader; Lei Jin; Robert B Levy
Journal:  Blood       Date:  2021-04-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.